Board of Directors
James R Howard-Tripp - Chairman and CEO
Mr. Howard-Tripp, who joined the StageZero (formerly GeneNews) Board in 2002, has specialized in the research, development and launch of innovative pharmaceutical products and the growth and development of the companies that research and market them. He has been involved in the management (GD Searle, Wyeth-Ayerst) and creation (Allelix, Labopharm, Dermacor) of several successful companies. He has 13 years' experience as a President and CEO and has sat on multiple Boards, most as Chairman. Most recently, as President and CEO of Labopharm, he oversaw the research, development and approval of 3 products and the launch of 2, with the lead product marketed in 19 countries (total end user sales approximately $100 million). During his tenure, Labopharm raised over $250 million in the public markets (US IPO $112 million in 2006) and achieved over $100 million in deal revenue (partners included: Sanofi-Aventis, Purdue Pharma, Merck Inc., Grünenthal, Angelini and Esteve). Additionally, he has served on various scientific and industry committees as well as several not-for-profit boards.
Mr. Howard-Tripp, who joined the StageZero (formerly GeneNews) Board in 2002, has specialized in the research, development and launch of innovative pharmaceutical products and the growth and development of the companies that research and market them. He has been involved in the management (GD Searle, Wyeth-Ayerst) and creation (Allelix, Labopharm, Dermacor) of several successful companies. He has 13 years' experience as a President and CEO and has sat on multiple Boards, most as Chairman. Most recently, as President and CEO of Labopharm, he oversaw the research, development and approval of 3 products and the launch of 2, with the lead product marketed in 19 countries (total end user sales approximately $100 million). During his tenure, Labopharm raised over $250 million in the public markets (US IPO $112 million in 2006) and achieved over $100 million in deal revenue (partners included: Sanofi-Aventis, Purdue Pharma, Merck Inc., Grünenthal, Angelini and Esteve). Additionally, he has served on various scientific and industry committees as well as several not-for-profit boards.
Rory Riggs - Director
Mr. Riggs is the Managing Member of Balfour LLC, an investment management company. Mr. Riggs is the past President of Biomatrix, Inc., a NYSE-listed company which successfully developed and marketed one of the leading viscosupplementation products in the United States, Synvisc®, for the treatment of osteoarthritis. Prior to Biomatrix, Mr. Riggs was Chief Executive Officer of RF&P Corporation and was also a Managing Director of PaineWebber Inc. Mr. Riggs holds a B.A. from Middlebury College, Vermont, and an MBA from the Graduate School of Business, Columbia University, New York.
Mr. Riggs is the Managing Member of Balfour LLC, an investment management company. Mr. Riggs is the past President of Biomatrix, Inc., a NYSE-listed company which successfully developed and marketed one of the leading viscosupplementation products in the United States, Synvisc®, for the treatment of osteoarthritis. Prior to Biomatrix, Mr. Riggs was Chief Executive Officer of RF&P Corporation and was also a Managing Director of PaineWebber Inc. Mr. Riggs holds a B.A. from Middlebury College, Vermont, and an MBA from the Graduate School of Business, Columbia University, New York.
Harry Glorikian - Director
Mr. Glorikian co-founded Scientia Advisors with 20 years of experience in the healthcare and life science industries. He is known worldwide as a leader in helping companies streamline their operations and accelerate their growth. Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Mr. Glorikian has a deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia’s sophisticated framework and proprietary analytic tools. Scienta was recently acquired by Precision for Medicine and Mr. Glorikian has joined the leadership team as Managing Director.
Mr. Glorikian co-founded Scientia Advisors with 20 years of experience in the healthcare and life science industries. He is known worldwide as a leader in helping companies streamline their operations and accelerate their growth. Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Mr. Glorikian has a deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia’s sophisticated framework and proprietary analytic tools. Scienta was recently acquired by Precision for Medicine and Mr. Glorikian has joined the leadership team as Managing Director.
Garth MacRae - Director
Mr. MacRae is a Director of Dundee Corporation, a merchant bank and financial services company, since 1991. Mr. MacRae is a Chartered Professional Accountant, having received his designation in Manitoba in 1957 and has been a member of the Ontario Institute of Chartered Accountants since 1970. In addition to being a Director of GeneNews and of Dundee Corporation, Mr. MacRae is a director of a number of other public and private companies.
Mr. MacRae is a Director of Dundee Corporation, a merchant bank and financial services company, since 1991. Mr. MacRae is a Chartered Professional Accountant, having received his designation in Manitoba in 1957 and has been a member of the Ontario Institute of Chartered Accountants since 1970. In addition to being a Director of GeneNews and of Dundee Corporation, Mr. MacRae is a director of a number of other public and private companies.
